Hyderabad: Home to Genome Valley, Hyderabad has emerged as one of the top life sciences clusters not just in India and Asia Pacific but also the world with with nearly $1.5 billion in investments being injected into the sector in the city over the past four years.The city, which accounts for around one-third of India’s pharmaceutical production, one-fifth of pharma exports, and a third of global vaccine production, has been rated among the top global life sciences hubs by realty consulting firm CBRE’s ‘Global Life Sciences Atlas’ report for 2025.Genome Valley houses over 200 biotech and pharma companies from 18 countries, including six of the world’s top 10 R&D companies, making Hyderabad the only city from India among the top seven in the Asia Pacific, along with Beijing, Melbourne, Shanghai, Singapore, Sydney, and Tokyo.Spread over 2,000 acres, Genome Valley currently has over 10 million sqft of R&D and manufacturing space. In 2024 alone, Hyderabad saw 2.4 million sqft of space leased by life sciences companies, up from 1.8 million sqft in 2023 and 0.6 million sqft in 2022, as per CBRE.Globally, the report said, the life sciences sector is influencing the growth of the realty sector, with over 35 million sqft of lab and R&D facilities under construction in 2024. In India too, the sector is witnessing its highest-ever office space leasing activity with the gross office leasing jumping 56% to about 5.8 million sqft in 2024 as against 2023.Globally, though the US leads with hubs such as Boston-Cambridge, San Francisco Bay Area, San Diego, Washington DC-Baltimore, Philadelphia, Raleigh-Durham, Los Angeles, Denver-Boulder, New York City, Houston, and Chicago in terms of total life sciences lab and R&D inventory, it is Beijing that leads globally when it comes to R&D space under construction.Anshuman Magazine, chairman & CEO – India, South-East Asia, Middle East & Africa, CBRE, said, “Hyderabad’s rise as a global life sciences manufacturing hub reflects the growing maturity and competitiveness of India’s life sciences sector. The city’s robust infrastructure, progressive policies, and exceptional scientific talent have made it a preferred destination for global pharmaceutical and biotech firms.”
